Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.61 |
| ▸ | CA1 | P00915 | 6/20 | 0.61 |
| ▸ | CA9 | Q16790 | 6/20 | 0.61 |
| ▸ | CA12 | O43570 | 5/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.61 |
| ▸ | CA5A | P35218 | 2/20 | 0.61 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | OGT | O15294 | 2/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.53 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 2/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | MIF | P14174 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26628312 | 0.87 | PTGS2 (0.67) | CA2CA1CA9CA12PTGS2 | |
| SCHEMBL1119554 | 0.87 | PTGS2 (0.66) | CA2CA1CA9CA12PTGS2 | |
| Bromide SCHEMBL6256547 | 0.85 | PTGS2 (0.64) | CA2CA1CA9CA12PTGS2 | |
| SCHEMBL18737325 | 0.83 | FLT3 (0.69) | CA2CA1CA9CA12PTGS2 | |
| SCHEMBL12522541 | 0.83 | FLT3 (0.73) | CA2CA1CA9CA12PTGS2 | |
| SCHEMBL12599087 | 0.83 | HSD17B1 (0.74) | CA2CA1CA9CA12PTGS2 | |
| SCHEMBL12450544 | 0.83 | CA2 (0.61) | CA2CA1CA9CA12PTGS2 | |
| SCHEMBL28337478 | 0.83 | FLT3 (0.65) | CA2CA1CA9CA12PTGS2 | |
| SCHEMBL3758635 | 0.83 | CA2 (0.66) | CA2CA1CA9CA12PTGS2 | |
| SCHEMBL28330114 | 0.83 | FLT3 (0.73) | CA2CA1CA9CA12PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509638-B1 | IODINE RADIOLABELLING METHOD | GE HEALTHCARE LTD (GB) | 2017-04-19 | — | — | EP | disclosed |
| US-20160022846-A1 | IODINE RADIOLABELLING METHOD | GE HEALTHCARE LTD (GB) | 2016-01-28 | — | — | US | disclosed |
| US-8894971-B2 | Iodine radiolabelling method | GE HEALTHCARE LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| CN-102770163-A | Iodine radiolabelling method | GE HEALTHCARE LTD | 2012-11-07 | — | — | CN | disclosed |
| EP-2509638-A1 | IODINE RADIOLABELLING METHOD | GE Healthcare UK Limited (GB) | 2012-10-17 | — | — | EP | disclosed |
| US-20120237444-A1 | IODINE RADIOLABELLING METHOD | GE HEALTHCARE LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| WO-2011070136-A1 | IODINE RADIOLABELLING METHOD | GE HEALTHCARE LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022846-A1 | IODINE RADIOLABELLING METHOD | BTD, BTN3A1, BTF3 | CA2 3375/4885CA1 2215/4885CA9 1275/4885 |
| US-20120237444-A1 | IODINE RADIOLABELLING METHOD | BTD, BTN3A1, BTF3 | CA2 3375/4885CA1 2215/4885CA9 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.